Lee Seongyong, Lee Ji Ye, Yoon Ra Gyoung, Kim Ji-Hoon, Hong Hyun Sook
Department of Radiology, Eulji Medical Center, Eulji University College of Medicine, Seoul 01830, Korea.
Department of Radiology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul 03080, Korea.
Cancers (Basel). 2020 Oct 1;12(10):2839. doi: 10.3390/cancers12102839.
Assessment of lymph node (LN) status in patients with papillary thyroid carcinoma (PTC) is often troublesome because of cervical LNs with indeterminate US (ultrasound) features. We aimed to explore whether Superb Microvascular Imaging (SMI) could be helpful for distinguishing metastasis from indeterminate LNs when combined with power Doppler US (PDUS). From 353 consecutive patients with PTC, LNs characterized as indeterminate by PDUS were evaluated by SMI to distinguish them from metastasis. Indeterminate LNs were reclassified according to the SMI, the malignancy risk of each category was assessed, and the diagnostic performance of suspicious findings on SMI was calculated. The incidence of US-indeterminate LNs was 26.9%. Eighty PDUS-indeterminate LNs (39 proven as benign, 41 proven as malignant) were reclassified into probably benign ( = 26), indeterminate ( = 20), and suspicious ( = 34) categories according to SMI, with malignancy risks of 19.2%, 20.0%, and 94.1%, respectively. After combining SMI with PDUS, 80.8% (21/26) of probably benign LNs and 94.1% (32/34) of suspicious LNs could be correctly diagnosed as benign and metastatic, respectively. The diagnostic sensitivity, specificity, and accuracy of categorizing LNs as suspicious based on SMI were 78.1%, 94.9%, and 86.3%, respectively. In conclusion, the combination of SMI with PDUS was helpful for the accurate stratification of indeterminate LNs based on US in patients with PTC.
由于甲状腺乳头状癌(PTC)患者的颈部淋巴结具有不确定的超声特征,评估其淋巴结(LN)状态往往很麻烦。我们旨在探讨与能量多普勒超声(PDUS)联合使用时,超微血管成像(SMI)是否有助于区分不确定淋巴结的转移情况。对353例连续的PTC患者中经PDUS判定为不确定的淋巴结进行SMI评估,以区分转移情况。根据SMI对不确定淋巴结重新分类,评估每类的恶性风险,并计算SMI可疑发现的诊断性能。超声不确定淋巴结的发生率为26.9%。80个PDUS不确定淋巴结(39个被证实为良性,41个被证实为恶性)根据SMI重新分类为可能良性(=26)、不确定(=20)和可疑(=34)三类,恶性风险分别为19.2%、20.0%和94.1%。将SMI与PDUS联合使用后,80.8%(21/26)的可能良性淋巴结和94.1%(32/34)的可疑淋巴结可分别正确诊断为良性和转移性。基于SMI将淋巴结分类为可疑的诊断敏感性、特异性和准确性分别为78.1%、94.9%和86.3%。总之,SMI与PDUS联合使用有助于对PTC患者基于超声的不确定淋巴结进行准确分层。